Rucci Carolyn M. 4

What Happened

• Carolyn M. Rucci, SVP and Chief Legal Officer of Akebia Therapeutics (AKBA), reported three sales on 2026-02-02: 16,846 shares, 25,382 shares and 27,544 shares, each at $1.39 per share. The three transactions totaled 69,772 shares for combined gross proceeds of approximately $96,983. These were sales (not purchases).

Key Details

• Transaction dates & prices: 2026-02-02 — 16,846 @ $1.39 ($23,416); 25,382 @ $1.39 ($35,281); 27,544 @ $1.39 ($38,286).
• Total shares sold: 69,772; total proceeds: ≈ $96,983.
• Footnotes in the filing indicate the sales were made under different circumstances: a Rule 10b5-1 trading plan adopted Sept 8, 2025, and automatic issuer sales to cover tax withholding tied to the vesting/settlement of restricted stock units granted on Jan 31 of 2023, 2024 and 2025.
• Filing: Report period 2026-02-02; Form 4 filed 2026-02-04 (appears timely based on the transaction date). The filing provided here did not list post-transaction beneficial ownership in the summary data supplied.

Context

• Several of the sales were automatic to satisfy tax-withholding on RSU vesting (i.e., issuer-sold shares to cover taxes), and at least one sale was executed under a prearranged Rule 10b5-1 plan. These types of transactions are typically routine and do not necessarily indicate a change in the insider’s view of the company.